Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof (2013)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/620,107, filed Apr 4, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,664,241 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence UsedRemaining | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| US 8,673,936 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| US 9,199,991 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| US 10,407,425 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| US 10,947,228 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Tenarx, Inc. | In force | High confidence | ||
| US 11,697,649 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Tenarx, Inc. | In force | High confidence | ||
| US 8,987,298 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| US 9,994,563 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | Biosplice Therapeutics, Inc. | In force | High confidence | ||
| Application 18/315,047 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof Abandoned Abandoned Jun 6, 2025 | Biosplice Therapeutics, Inc. | Abandoned | Abandoned Jun 6, 2025 | ||
| Application 19/231,090 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof Pending Not granted | BioSplice Therapeutics, Inc. | Pending | Not granted |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Biosplice Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.